Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  HIV Infection

  Free Subscription

Articles published in Nat Med

Retrieve available abstracts of 45 articles:
HTML format

Single Articles

    November 2023

  1. Viral, cellular and immune aspects of non-suppressible HIV-1 viremia.
    Nat Med. 2023 Nov 23. doi: 10.1038/s41591-023-02688.

  2. MOHAMMADI A, Etemad B, Zhang X, Li Y, et al
    Viral and host mediators of non-suppressible HIV-1 viremia.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02611.
    PubMed     Abstract available

  3. Determining the longevity and dynamics of HIV-1 neutralizing activity.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02592.

  4. SCHOMMERS P, Kim DS, Schlotz M, Kreer C, et al
    Dynamics and durability of HIV-1 neutralization are determined by viral replication.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02582.
    PubMed     Abstract available

  5. ZHANG L, Iannuzzi S, Chaturvedula A, Irungu E, et al
    Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02615.
    PubMed     Abstract available

  6. SHAHMANESH M, Chimbindi N, Cowan FM
    Person-centered HIV PrEP for cisgender women.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02618.

    October 2023
  7. EMIRU T, Getachew D, Murphy M, Sedda L, et al
    Evidence for a role of Anopheles stephensi in the spread of drug and diagnosis-resistant malaria in Africa.
    Nat Med. 2023 Oct 26. doi: 10.1038/s41591-023-02641.
    PubMed     Abstract available

  8. MOORE M, Stansfield S, Donnell DJ, Boily MC, et al
    Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
    Nat Med. 2023 Oct 5. doi: 10.1038/s41591-023-02564.
    PubMed     Abstract available

  9. DASHTI A, Sukkestad S, Horner AM, Neja M, et al
    AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
    Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02570.
    PubMed     Abstract available

    September 2023
  10. GUNST JD, Hojen JF, Pahus MH, Rosas-Umbert M, et al
    Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
    Nat Med. 2023 Sep 11. doi: 10.1038/s41591-023-02547.
    PubMed     Abstract available

    August 2023
  11. ZHANG Y, Li J, Xie Y, Wu D, et al
    Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02519.
    PubMed     Abstract available

  12. BRANCHE AR, Rouphael NG, Diemert DJ, Falsey AR, et al
    Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02503.
    PubMed     Abstract available

    Balancing the risks of HIV transmission at low viral load.
    Nat Med. 2023 Aug 3. doi: 10.1038/d41591-023-00068.

    July 2023
  14. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A
    Community-engaged Mpox vaccination provides lessons for equitable health care in the United States.
    Nat Med. 2023 Jul 19. doi: 10.1038/s41591-023-02447.

  15. SERRANO-VILLAR S, Tincati C, Raju SC, Saenz JS, et al
    Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.
    Nat Med. 2023;29:1738-1749.
    PubMed     Abstract available

    June 2023
  16. TELFORD E, Grinsztejn B, Olsen IC, Pulik N, et al
    The international Unity study for antivirals against mpox is a blueprint for future epidemics.
    Nat Med. 2023 Jun 30. doi: 10.1038/s41591-023-02393.

  17. LISCO A, Lange C, Manion M, Kuriakose S, et al
    Immune reconstitution inflammatory syndrome drives emergence of HIV drug resistance from multiple anatomic compartments in a person living with HIV.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02387.
    PubMed     Abstract available

  18. Local immune activation shapes systemic HIV reservoirs.
    Nat Med. 2023;29:1326-1327.

    May 2023
    First two patients receive CAR T cell therapy for HIV.
    Nat Med. 2023 May 9. doi: 10.1038/d41591-023-00042.

    March 2023
  20. ESMAIL A, Randall P, Oelofse S, Tomasicchio M, et al
    Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial.
    Nat Med. 2023 Mar 9. doi: 10.1038/s41591-023-02247.
    PubMed     Abstract available

    February 2023

  21. HIV-1 cure after CCR5Delta32/Delta32 allogeneic hematopoietic stem cell transplantation.
    Nat Med. 2023 Feb 27. doi: 10.1038/s41591-023-02215.

  22. JENSEN BO, Knops E, Cords L, Lubke N, et al
    In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32/Delta32 allogeneic hematopoietic stem cell transplantation.
    Nat Med. 2023 Feb 20. doi: 10.1038/s41591-023-02213.
    PubMed     Abstract available

    January 2023
  23. MCKENNA L, Frick M, Angami K, Dubula V, et al
    The 1/4/6x24 campaign to cure tuberculosis quickly.
    Nat Med. 2023 Jan 10. doi: 10.1038/s41591-022-02136.

  24. TAN ST, Kwan AT, Rodriguez-Barraquer I, Singer BJ, et al
    Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.
    Nat Med. 2023 Jan 2. doi: 10.1038/s41591-022-02138.
    PubMed     Abstract available

    December 2022
  25. KEUROGHLIAN AS, Keatley J, Shaikh S, Radix AE, et al
    The context, science and practice of gender-affirming care.
    Nat Med. 2022 Dec 15. doi: 10.1038/s41591-022-02082.

    October 2022
  26. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed     Abstract available

  27. GUNST JD, Pahus MH, Rosas-Umbert M, Lu IN, et al
    Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
    Nat Med. 2022 Oct 17. pii: 10.1038/s41591-022-02023.
    PubMed     Abstract available

    August 2022
  28. GILBERT PB, Huang Y, deCamp AC, Karuna S, et al
    Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.
    Nat Med. 2022 Aug 22. pii: 10.1038/s41591-022-01953.
    PubMed     Abstract available

  29. DE BAETSELIER I, Van Dijck C, Kenyon C, Coppens J, et al
    Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium.
    Nat Med. 2022 Aug 12. pii: 10.1038/s41591-022-02004.
    PubMed     Abstract available

    July 2022
    Long-acting agents for HIV treatment and prevention.
    Nat Med. 2022 Jul 22. pii: 10.1038/s41591-022-01917.

    June 2022
  31. TEGALLY H, Moir M, Everatt J, Giovanetti M, et al
    Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.
    Nat Med. 2022 Jun 27. pii: 10.1038/s41591-022-01911.
    PubMed     Abstract available

    May 2022
  32. JULG B, Stephenson KE, Wagh K, Tan SC, et al
    Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Nat Med. 2022 May 12. pii: 10.1038/s41591-022-01815.
    PubMed     Abstract available

    April 2022
  33. CASAZZA JP, Cale EM, Narpala S, Yamshchikov GV, et al
    Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
    Nat Med. 2022 Apr 11. pii: 10.1038/s41591-022-01762.
    PubMed     Abstract available

    March 2022
  34. ARSENAULT C, Gage A, Kim MK, Kapoor NR, et al
    COVID-19 and resilience of healthcare systems in ten countries.
    Nat Med. 2022 Mar 14. pii: 10.1038/s41591-022-01750.
    PubMed     Abstract available

    February 2022
  35. O'LEARY K
    HIV variant causes concern.
    Nat Med. 2022 Feb 14. pii: 10.1038/d41591-022-00034.

    January 2022
  36. MILLER JS, Davis ZB, Helgeson E, Reilly C, et al
    Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial.
    Nat Med. 2022 Jan 31. pii: 10.1038/s41591-021-01651.
    PubMed     Abstract available

  37. O'LEARY K
    HIV and skin cancer risk.
    Nat Med. 2022 Jan 6. pii: 10.1038/d41591-022-00001.

    December 2021

  38. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.

  39. DEEKS SG, Archin N, Cannon P, Collins S, et al
    Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.
    Nat Med. 2021 Dec 1. pii: 10.1038/s41591-021-01590.
    PubMed     Abstract available

  40. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.

  41. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available

    November 2021
  42. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed     Abstract available

    October 2021
  43. BLAZKOVA J, Gao F, Marichannegowda MH, Justement JS, et al
    Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy.
    Nat Med. 2021 Oct 28. pii: 10.1038/s41591-021-01503.
    PubMed     Abstract available

  44. STEPHENSON KE, Julg B, Tan CS, Zash R, et al
    Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
    Nat Med. 2021 Oct 7. pii: 10.1038/s41591-021-01509.
    PubMed     Abstract available

  45. MATTHEWS RP, Patel M, Barrett SE, Haspeslagh L, et al
    Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01479.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.